Patents by Inventor Ingegerd Hellstrom
Ingegerd Hellstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200325215Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.Type: ApplicationFiled: July 1, 2020Publication date: October 15, 2020Applicants: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.Inventors: Ingegerd HELLSTROM, Karl-Erik HELLSTROM, John RAYCRAFT, Christian FERMÉR, Eva RÖIJER
-
Publication number: 20180217158Abstract: The present invention features, inter alia, compositions and methods related to the detection of HE4-expressing tumor cells in a subject. The methods include detection of anti-HE4 antibodies in a biological sample obtained from the subject. The methods are useful for diagnosis and monitoring the efficacy of treatments for cancers in which HE4 is expressed, for example, ovarian cancer.Type: ApplicationFiled: January 25, 2018Publication date: August 2, 2018Applicant: University of Washington through its Center for CommercializationInventors: Karl Erik Hellstrom, Ingegerd Hellstrom, Pu Liu, Jade Jaffar, Elizabeth Swisher
-
Publication number: 20180057575Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.Type: ApplicationFiled: October 19, 2017Publication date: March 1, 2018Applicants: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.Inventors: Ingegerd HELLSTROM, Karl-Erik HELLSTROM, John RAYCRAFT, Christian FERMÉR, Eva RÖIJER
-
Patent number: 9822169Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.Type: GrantFiled: February 17, 2011Date of Patent: November 21, 2017Assignees: PACIFIC NORTHWEST DIABETES RESEARCH INSTITUTE, FUJIREBIO DIAGNOSTICS, INC.Inventors: Ingegerd Hellstrom, Karl-Erik Hellstrom, John Raycraft, Christian Fermér, Eva Roijer
-
Publication number: 20160033512Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: July 27, 2015Publication date: February 4, 2016Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20150353629Abstract: The invention includes the use of the HE/HE4a markers to assess ovarian cancer in a subject. Included also are compositions and methods of using HE/HE4a marker for diagnosis, grading and staging of ovarian cancers, determining prognosis and treatment effectiveness of a subject who has been diagnosed with ovarian cancer.Type: ApplicationFiled: February 17, 2011Publication date: December 10, 2015Inventors: Ingegerd Hellstrom, Karl-Erik Hellstrom, John Raycraft, Christian Fermér, Eva Röijer
-
Patent number: 9090712Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: GrantFiled: August 6, 2009Date of Patent: July 28, 2015Assignee: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20130224772Abstract: The present invention features, inter alia, compositions and methods related to the detection of HE4-expressing tumor cells in a subject. The methods include detection of anti-HE4 antibodies in a biological sample obtained from the subject. The methods are useful for diagnosis and monitoring the efficacy of treatments for cancers in which HE4 is expressed, for example, ovarian cancer.Type: ApplicationFiled: August 26, 2011Publication date: August 29, 2013Applicant: University of Washington through its Center for CommercializationInventors: Karl Erik Hellstrom, Ingegerd Hellstrom, Pu Liu, Jade Jaffar, Elizabeth Swisher
-
Publication number: 20110300186Abstract: Compositions containing an optionally surface-functionalized mesoporous support and a biologically active agent, and pharmaceutical compositions of the same, are provided herein. Such compositions can be useful in the treatment of tumors, for example, by injection of the composition at a location near the site of the tumor.Type: ApplicationFiled: April 14, 2011Publication date: December 8, 2011Applicants: Battelle Memorial Institute, University of Washington through its Center for CommercializationInventors: Karl Erik Hellstrom, Ingegerd Hellstrom, Pu Liu, Huafeng Wei, Jun Liu, Chenghong Lei, Baowei Chen, Xiaolin Li
-
Publication number: 20110104675Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: May 17, 2010Publication date: May 5, 2011Applicant: Pacific Northwest Research InstituteInventors: Nathalie Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Patent number: 7745159Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: GrantFiled: February 13, 2004Date of Patent: June 29, 2010Inventors: Nathalie B Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Publication number: 20100047818Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: August 6, 2009Publication date: February 25, 2010Applicant: PACIFIC NORTHWEST RESEARCH INSTITUTEInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Patent number: 7547681Abstract: The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.Type: GrantFiled: January 20, 2004Date of Patent: June 16, 2009Assignee: University of WashingtonInventors: Nathalie B Scholler, Mary L Disis, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Publication number: 20090104684Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: August 8, 2007Publication date: April 23, 2009Applicants: Pacific Northwest Research Institute, University of WashingtonInventors: Michel Schummer, INGEGERD HELLSTROM, Karl Erik Hellstrom, JEFFREY A. LEDBETTER, MARTHA HAYDEN-LEDBETTER
-
Publication number: 20090042224Abstract: In one embodiment, methods are provided for assessing the presence of mesothelin-expressing tumor cells in a human subject. In another embodiment, methods are provided for monitoring the efficacy of treatment of a human cancer patient diagnosed with a mesothelin-expressing tumor.Type: ApplicationFiled: June 5, 2008Publication date: February 12, 2009Applicant: WASHINGTON, UNIVERSITY OFInventors: Ingegerd Hellstrom, Karl Erik Hellstrom, Yi Yang
-
Publication number: 20070286860Abstract: Compositions and methods are provided for inducing anti-tumor immunity. More specifically, tumor cells and recombinant constructs are provided that express a cell surface CD83 polypeptide and/or a cell surface expressed antibody that specifically binds to an immune cell receptor, particularly an antibody that specifically binds to CD137. The invention also provides recombinant expression constructs comprising polynucleotides that encode a cell surface CD83 polypeptide, a cell surface expressed anti-immune cell receptor antibody, and/or at least one tumor antigen, and the related expressed products.Type: ApplicationFiled: March 25, 2005Publication date: December 13, 2007Applicant: Washington Research FoundationInventors: Karl Hellstrom, Ingegerd Hellstrom, Yi Yang
-
Patent number: 7270960Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble and cell surface forms of HE4a polypeptides, including HE4a that is overexpressed in ovarian carcinomas. In particular the invention provides a nucleic acid sequence encoding HE4a, and also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a HE4a polypeptide with a molecule naturally occurring in soluble and/or cell surface form in a sample from such a subject, and by hybridization screening using an HE4a nucleotide sequence, as well as other related advantages.Type: GrantFiled: August 28, 2002Date of Patent: September 18, 2007Assignee: Pacific Northwest Research InstituteInventors: Ingegerd Hellstrom, Jeffrey A. Ledbetter, Martha Hayden-Ledbetter
-
Publication number: 20040219161Abstract: The invention provides compositions and methods directed to cell surface receptor antigen specific vaccines. More specifically, vaccines are provided that induce or enhance host antibody titers specific for cell surface receptor antigens and that include recombinant expression constructs containing nucleic acids encoding a target cell surface receptor antigen and one or more immune response altering molecules, or the expressed products themselves.Type: ApplicationFiled: January 20, 2004Publication date: November 4, 2004Applicant: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Mary L. Disis, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Patent number: 6770445Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: GrantFiled: February 25, 2000Date of Patent: August 3, 2004Assignee: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom
-
Publication number: 20040142396Abstract: The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages.Type: ApplicationFiled: February 13, 2004Publication date: July 22, 2004Applicant: Pacific Northwest Research InstituteInventors: Nathalie B. Scholler, Ingegerd Hellstrom, Karl Erik Hellstrom